Logo
x

Search

Subscribe Now

shionogi

Shionogi Partners with Maze Therapeutics for MZE001’s Rights to Treat Pompe Disease

Shionogi Partners with Maze Therapeutics for MZE001’s Rights to Treat Pompe Disease

  • May 10, 2024
Shionogi Reports the P-III Trial Results for Ensitrelvir as a Treatment of Common COVID-19 Symptoms

Shionogi Reports the P-III Trial Results for Ensitrelvir as a Treatment of Common COVID-19 Symptoms

  • February 12, 2024
Shionogi Initiated P-I/II/III Clinical Trial (Part 2) and P-III Additional Dose Clinical Trial of S-268019 for COVID-19

Shionogi Initiated P-I/II/III Clinical Trial (Part 2) and P-III Additional Dose Clinical Trial of S-268019 for COVID-19

  • January 17, 2023
Shionogi Seeks Japan Approval of S-268019 for the Treatment of COVID-19

Shionogi Seeks Japan Approval of S-268019 for the Treatment of COVID-19

  • November 24, 2022
Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacteria...

  • November 7, 2022
Shionogi Presents Real-World Evidence of Fetroja (cefiderocol) for Treatment Resistant Bacterial Infections at IDWeek 2022

Shionogi Presents Real-World Evidence of Fetroja (cefiderocol) for Treatment Resistant Bacterial Infections at IDWeek 2022

  • October 20, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.